SEAM-RA: Maintenance of Remission Better After Withdrawal of Methotrexate Than Withdrawal of Etanercept

November 5-9, 2020; Virtual Meeting
At Week 48, SDAI remission maintained in 49.5% of patients receiving etanercept monotherapy vs 28.7% of patients receiving methotrexate monotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 221 KB
Released: November 12, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Related Content

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

Released: November 13, 2020

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

Released: November 13, 2020

CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: November 13, 2020

San Antonio cohort study from ACR 2020 on potential cardiotoxicity of hydroxychloroquine in patients with rheumatoid arthritis (RA), as reported by CCO

Released: November 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue